This was similar to the previous findings on melanoma patients treated with anti-CTLA-4 inhibitors, where bacterial metabolism pathways involved in B vitamin biosynthesis were indicated to protect patients from immune-related colitis [35]. This evidence concerns the gene CTLA4 and melanoma.